Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.

Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC.

J Clin Psychiatry. 2004 Oct;65(10):1377-88.

PMID:
15491242
2.

Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies.

Citrome L, Jaffe A, Levine J, Lindenmayer JP.

J Clin Psychiatry. 2005 Dec;66(12):1512-6. Review.

PMID:
16401150
3.

Polypharmacy with second-generation antipsychotics: a review of evidence.

Pandurangi AK, Dalkilic A.

J Psychiatr Pract. 2008 Nov;14(6):345-67. doi: 10.1097/01.pra.0000341890.05383.45. Review.

PMID:
19057237
4.

Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature.

Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV.

J Clin Psychiatry. 2002 Oct;63(10):892-909. Review.

PMID:
12416599
5.

Treatment-resistant schizophrenia: reviewing the options and identifying the way forward.

Hellewell JS.

J Clin Psychiatry. 1999;60 Suppl 23:14-9. Review.

6.
7.
8.

The need for individualised antipsychotic drug therapy in patients with schizophrenia.

Pani L.

Eur Rev Med Pharmacol Sci. 2009 Nov-Dec;13(6):453-9. Review.

PMID:
20085126
9.

Optimisation of prescription in patients with long-term treatment-resistant schizophrenia.

Maiocchi L, Bernardi E.

Australas Psychiatry. 2013 Oct;21(5):446-8. doi: 10.1177/1039856213492862. Epub 2013 Jul 19. Review.

PMID:
23873896
10.

Rational antipsychotic polypharmacy.

Kennedy NB, Procyshyn RM.

Can J Clin Pharmacol. 2000 Autumn;7(3):155-9. Review.

PMID:
11044761
11.

Antipsychotic polypharmacy in schizophrenia: benefits and risks.

Barnes TR, Paton C.

CNS Drugs. 2011 May;25(5):383-99. doi: 10.2165/11587810-000000000-00000. Review.

PMID:
21476610
12.

Antipsychotic polypharmacy.

Ananth J, Parameswaran S, Gunatilake S.

Curr Pharm Des. 2004;10(18):2231-8. Review.

PMID:
15281898
13.

A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy.

Honer WG, Procyshyn RM, Chen EY, MacEwan GW, Barr AM.

J Psychiatry Neurosci. 2009 Nov;34(6):433-42. Review.

14.

[Antipsychotic drug combinations in the treatment of schizophrenia. A review of the literature].

Gazdag G, Tolna J, Bitter I.

Neuropsychopharmacol Hung. 2012 Sep;14(3):189-95. Review. Hungarian.

15.

Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies.

Verdoux H, Tournier M, Bégaud B.

Acta Psychiatr Scand. 2010 Jan;121(1):4-10. doi: 10.1111/j.1600-0447.2009.01425.x. Epub 2009 Jun 25. Review.

PMID:
20059452
16.

Clinical guideline recommendations for antipsychotic long-acting injections.

Kane JM, Garcia-Ribera C.

Br J Psychiatry Suppl. 2009 Nov;52:S63-7. doi: 10.1192/bjp.195.52.s63. Review.

PMID:
19880920
17.

The long-acting depot antipsychotic drugs.

Pandarakalam JP.

Hosp Med. 2003 Oct;64(10):603-8. Review.

PMID:
14584241
18.

The evolution of antipsychotic switch and polypharmacy in natural practice--a longitudinal perspective.

Tsutsumi C, Uchida H, Suzuki T, Watanabe K, Takeuchi H, Nakajima S, Kimura Y, Tsutsumi Y, Ishii K, Imasaka Y, Kapur S.

Schizophr Res. 2011 Aug;130(1-3):40-6. doi: 10.1016/j.schres.2011.05.013. Epub 2011 May 31. Review.

PMID:
21624824
19.

Exploring the potential effect of polypharmacy on the hematologic profiles of clozapine patients.

Shuman MD, Trigoboff E, Demler TL, Opler LA.

J Psychiatr Pract. 2014 Jan;20(1):50-8. doi: 10.1097/01.pra.0000442937.61575.26. Review.

PMID:
24419309
20.

Antipsychotics: to combine or not to combine?

Sagud M, Vuksan-Ćusa B, Zivković M, Vlatković S, Kramarić M, Bradaš Z, Mihaljević-Peleš A.

Psychiatr Danub. 2013 Sep;25(3):306-10. Review.

Supplemental Content

Support Center